Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Promyelocytic, Acute 27 Leukemia, Myeloid, Acute 27 Leukemia 16 Myelodysplastic Syndromes 13 Multiple Myeloma 9 Neuroblastoma 5 Melanoma 5 Lung Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Pancreatic Neoplasms 4 Neoplasm Metastasis 4 Myeloproliferative Disorders 4 Myelodysplastic-Myeloproliferative Diseases 4 Leukemia, Myelomonocytic, Acute 4 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4 Leukemia, Monocytic, Acute 4 Leukemia, Megakaryoblastic, Acute 4 Leukemia, Erythroblastic, Acute 4 Hematologic Neoplasms 4 Congenital Abnormalities 4 Uterine Cervical Neoplasms 3 Leukemia, Myelomonocytic, Chronic 3 Anemia, Refractory, with Excess of Blasts 3 Thrombocytopenia 2 Small Cell Lung Carcinoma 2 Prostatic Neoplasms 2 Primary Myelofibrosis 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pathologic Complete Response 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2

Interventions

ribociclib 1 Tretinoin 1 Letrozole 1 Goserelin 1 Drug Therapy 1 Chemotherapy, Adjuvant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HER2 Negative Breast Cancer × Tretinoin × Clear all

NCT06731140 2025-11-17

Resilire

Fudan University

Phase 2 Recruiting

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡